NeXT Dx
Use
NeXT Dx is a comprehensive genomic profiling (CGP) test suitable for patients with solid tumors. It uses augmented whole exome and transcriptome sequencing to provide insights into cancer care. By detecting fusions from RNA, reporting small nucleotide variants (SNVs), insertions and deletions (indels), and copy number alterations (CNAs), it enhances the accuracy of tumor mutational burden (TMB) assessments and highlights homologous recombination repair (HRR) gene variants. The test aids in identifying effective therapies or clinical trials for cancer patients.
Special Instructions
Not provided.
Limitations
The genomic findings from NeXT Dx are not prescriptive or conclusive for the labeled use of any specific therapeutic products. Tests may result in no reportable alterations and/or no associated therapies or clinical trials. Negative results do not rule out the presence of an alteration. The test has not been cleared or approved by the FDA but is performed in a CLIA-certified laboratory.
Methodology
NGS
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue
Volume
Not provided
Minimum Volume
Not provided